Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine in Advanced Myelodysplastic Syndromes
NCT00003123Phase 2Unknown
- Start
- Aug 1997
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amifostine in myelodysplastic syndrome (MDS). Primary endpoints: Overall Hematologic Response Rate at 6 months and Toxic Effects of Amifostine. Status: unknown.
02
Drugs
amifostine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00003123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003123.